National Institutes of Health (NIH) has awarded Modulated Imaging Inc a $1.8 million SBIR Phase II grant to further develop the company’s Ox-Imager CS technology to help predict and manage the treatment of diabetic foot ulcers.
The grant will help support three clinical studies, as well as the research and development of a point-of-care diagnostic system, according to a media release from the Irvine, Calif-based company.
“Our Ox-Imager device is a non-contact optical imaging system which provides physicians with real-time information on tissue health,” says Amaan Mazhar, PhD, Modulated Imaging’s vice president of R&D and the grant’s principal investigator, in the release.
“This grant from the NIH will allow us to further refine the Ox-Imager through clinical studies and technology development. Our goal as a company is to eliminate the inevitability of amputations due to diabetic foot ulcers,” he adds.
The technology is currently pending FDA clearance.
[Source(s): Modulated Imaging Inc, PRWeb]
